Overview
- The joint study will enroll 100 adults starting GLP‑1 weight‑loss therapy and split them into a watch‑monitored group and a standard‑guidance group.
- Participants using the Galaxy Watch 8 will provide continuous biometric data such as activity, heart rate, and on‑device body‑composition estimates while researchers use DXA scans to measure changes in muscle mass.
- Study organizers say the trial will test whether real‑time wearable metrics and personalized exercise guidance can help patients and clinicians identify and limit muscle loss during GLP‑1 treatment.
- No results are yet available; the project is in its launch and enrollment phase and will need trial data and clinical analysis before effectiveness is established.
- The effort builds on prior Samsung–Massachusetts General collaborations and responds to growing concern about muscle loss as GLP‑1 drugs gain popularity, with one report provisionally saying nearly one in five U.S. adults have tried these medications.